Expert opinion on therapeutic patents
-
Expert Opin Ther Pat · Sep 2010
Transplantation of two populations of stem cells to improve engraftment: WO2008060932.
The application is in the field of haematopoietic stem cells (HSCs) and cellular therapy. ⋯ The application claims the transplantation of at least two populations of HSCs, separated by an interval of time between 2 and 24 h, to improve the outcome of HSC transplantation for the treatment of haematologic diseases. The procedure may be extended to other types of stem cells for treating a broad range of diseases and injuries.
-
Expert Opin Ther Pat · Sep 2010
ReviewTransient receptor potential vanilloid-1 antagonists: a survey of recent patent literature.
Transient receptor potential vanilloid-1 (TRPV1, vanilloid receptor-1) is a nonspecific cation channel that can be activated by multiple endogenous stimuli and by capsaicin, the active ingredient in chili peppers. TRPV1 is expressed predominantly on sensory neurons where it is proposed to serve as a key nodal point in pain transmission pathways. Pharmacological blockade of TRPV1 represents a compelling strategy for the treatment of a variety of disease states, particularly those requiring chronic pain management. AREA COVERED IN THE REVIEW: This review summarizes patent literature and progress in defining the utility of small molecule TRPV1 antagonists during 2008-2009. ⋯ The continued profusion of reports, in both the primary and patent literature, attests to the sustained interest in the TRPV1 class of therapeutics. Although a number of compounds have now been brought forward for human clinical trials, the therapeutic utility of TRPV1 antagonists is yet to be validated unequivocally.
-
Expert Opin Ther Pat · Sep 2010
Ex vivo fucosylation of stem cells to improve engraftment: WO2004094619.
The application is in the field of haematopoietic stem cell (HSC) and umbilical cord blood (CB) transplantation. ⋯ Treatment of CB stem cells with FTVI, ex vivo prior to transplantation, may reduce the delay of engraftment of CB stem cells to the BM and the risk of early infections associated with CB transplants, particularly in adults. It may improve the outcome and rate of success of CB transplantation. The application claims the use of fucosyltransferase for improving the engraftment of CB HSCs to the BM for the treatment of haematologic diseases. The procedure may be used to improve the engraftment of HSCs from other sources and other types of stem cells, on transplantation, particularly when administered intravenously.